Literature DB >> 32691965

Antihypertensive activity and molecular interactions of irbesartan in complex with 2-hydroxypropyl-β-cyclodextrin.

Georgios Leonis1, Eirini Christodoulou1, Dimitrios Ntountaniotis1, Maria V Chatziathanasiadou2, Thomas Mavromoustakos1, Nikolaos Naziris3, Maria Chountoulesi3, Costas Demetzos3, Georgia Valsami3, Dimitrios E Damalas4, Andreas G Tzakos2, Nikolaos S Thomaidis4, Vlasios Karageorgos5, Georgios Liapakis5.   

Abstract

Irbesartan (IRB) exerts beneficial effects either alone or in combination with other drugs on numerous diseases, such as cancer, diabetes, and hypertension. However, due to its high lipophilicity, IRB does not possess the optimum pharmacological efficiency. To circumvent this problem, a drug delivery system with 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) was explored. The 1:1 complex between IRB and 2-HP-β-CD was identified through ESI QTF HRMS. Dissolution studies showed a higher dissolution rate of the lyophilized IRB-2-HP-β-CD complex than the tablet containing IRB at pH = 1.2. DSC results revealed the differences of the thermal properties between the complex and various mixtures consisting of the two components, namely IRB and 2-HP-β-CD. Interestingly, depending on the way the mixture preparation was conducted, different association between the two components was observed. Molecular dynamics (MD) simulations predicted the favorable formation of the above complex and identified the dominant interactions between IRB and 2-HP-β-CD. In vitro pharmacological results verified that the inclusion complex not only preserves the binding affinity of IRB for AT1R receptor, but also it slightly increases it. As the complex formulation lacks the problems of the tablet, our approach is a promising new way to improve the efficiency of IRB.
© 2020 John Wiley & Sons A/S.

Entities:  

Keywords:  2-hydroxypropyl-β-cyclodextrin; binding assays; differential scanning calorimetry; hypertension; irbesartan; mass spectrometry; molecular dynamics

Mesh:

Substances:

Year:  2020        PMID: 32691965     DOI: 10.1111/cbdd.13664

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  3 in total

1.  Losartan Interactions with 2-Hydroxypropyl-β-CD.

Authors:  Vasiliki Palli; Georgios Leonis; Nikoletta Zoupanou; Nikitas Georgiou; Maria Chountoulesi; Nikolaos Naziris; Demeter Tzeli; Costas Demetzos; Georgia Valsami; Konstantinos D Marousis; Georgios A Spyroulias; Thomas Mavromoustakos
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

Review 2.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

3.  Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization.

Authors:  Narendar Dudhipala; Swetha Ettireddy; Ahmed Adel Ali Youssef; Goverdhan Puchchakayala
Journal:  Molecules       Date:  2021-12-13       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.